Atopic Dermatitis

Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release.

According to analyses of new phase 3 data, patients with atopic dermatitis that were treated with Vtama cream 1% maintained long-term improvement even after stopping treatment, Dermavant announced in a press release.

Patients with atopic dermatitis and plaque psoriasis who were treated with a topical phosphodiesterase 4 inhibitor exhibited significant improvement, according to a study.

Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.

The FDA has granted priority review to omalizumab as a treatment for food allergy after accidental exposure, according to a press release.

Healio’s top atopic dermatitis stories described evidence supporting various treatments, including two reviews of dozens of approaches, as well as physical and mental comorbidities, among other topics.

Two new practice parameters from a joint task force published in Annals of Allergy, Asthma & Immunology provide evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis.

Arcutis reported its financial results for the third quarter of 2023, which included a total revenue of $38.1 million and a 70% increase in Zoryve revenue, according to a company press release.

The FDA approved an expanded indication for tralokinumab-ldrm to include children aged 12 to 17 years with moderate to severe atopic dermatitis not adequately controlled with topical therapies, according to a press release from Leo Pharma.